|
1.
|
Quantification of trace $^{227}$Ac and other radionuclidic impurities in mass-separated $^{225}$Ac samples produced at CERN-MEDICIS
/ Johnson, Jake D (Leuven U.) ; Bernerd, Cyril (Leuven U. ; CERN) ; Bruchertseifer, Frank (Unlisted, DE) ; Cocolios, Thomas E (Leuven U.) ; Deseyn, Marie (Leuven U.) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Heines, Michael (Leuven U.) ; Keppens, Max (Leuven U.) ; Lambert, Laura (CERN) ; Meurrens, Nathan (Leuven U.) et al.
$^{225}$Ac is a promising candidate medical radionuclide for targeted alpha therapy of advanced stage cancers. One of the main production pathways is the high-energy proton spallation of thorium-based targets, that requires an efficient, nuclide-selective separation method to recover $^{225}$Ac from hundreds of co-produced spallation and fission products. [...]
2025 - 14 p.
- Published in : Sci. Rep. 15 (2025) 23563
Fulltext: PDF;
|
|
|
2.
|
Novel radionuclides: demand, production and distribution for translational research in Europe
/ Radzina, Maija (CERN ; Latvia U.) ; Saule, Laura (Latvia U.) ; Mamis, Edgars (CERN ; Latvia U.) ; Pajuste, Elina (Latvia U.) ; Koester, Ulli (Laue-Langevin Inst.) ; Cocolios, Thomas Elias (Leuven U.) ; Proskurins, Jevgenijs (Unlisted, LV) ; Kalnina, Patricija (Latvia U.) ; Zabolockis, Rudolfs Janis (Latvia U.) ; Palskis, Kristaps (CERN ; Latvia U.) et al.
Background: In the feld of medical and scientifc research, radionuclides are used to investigate various physiological and pathological processes. PRISMAP - the European medical radionuclide programme was created to bring together production facilities including intense neutron sources, an isotope mass separation facility, highpower accelerators, biomedical research institutes, and hospitals to support medical research [...]
2024 - 16 p.
- Published in : EJNMMI Radiopharmacy and Chemistry 9 (2024) 85
Published version: PDF;
|
|
|
3.
|
|
|
4.
|
The SPES Laser Ion Source: Time Structure and Laser Enhancement Measurements with Sm$^{+}$ beam
/ Khwairakpam, O S (Siena U. ; INFN, Legnaro) ; Mancheva, R (CERN ; KU Leuven, Dept. Phys. Astron.) ; Au, M (CERN) ; Bernerd, C (CERN ; KU Leuven, Dept. Phys. Astron.) ; Centofante, L (INFN, Legnaro) ; Chrysalidis, K (CERN) ; Crepieux, B (CERN) ; Fedosseev, V N (CERN) ; Heinke, R (CERN) ; Marchi, T (INFN, Legnaro) et al.
A two-step resonance photo-ionization scheme has been used to ionize samarium atoms in the SPES tantalum hot-cavity ion source. The effect of the ion load on the ion beam time structure and the laser enhancement of the ion yield has been studied at different ion source temperatures. [...]
2024 - 6 p.
- Published in : J. Phys. : Conf. Ser. 2743 (2024) 012066
Fulltext: PDF;
In : 20th International Conference on Ion Sources (ICIS 2023), Victoria, BC, Canada, 17 - 22 Sep 202, pp.012066
|
|
|
5.
|
Target Development towards First Production of High-Molar- Activity $^{44g}$Sc and $^{47}$Sc by Mass Separation at CERN-MEDICIS
/ Mamis, Edgars (CERN ; Latvia U.) ; Duchemin, Charlotte (CERN) ; Berlin, Valentina (CERN) ; Bernerd, Cyril (CERN) ; Bovigny, Mathieu (CERN) ; Chevallay, Eric (CERN) ; Crepieux, Bernard (CERN) ; Gadelshin, Vadim Maratovich (Mainz U., Inst. Phys.) ; Heinke, Reinhard (CERN) ; Hernandez, Ronaldo Mendez (CERN ; Havana, ISCTN) et al.
The radionuclides 43Sc, 44g/mSc, and 47Sc can be produced cost-effectively in sufficient yield for medical research and applications by irradiating natTi and natV target materials with protons. Maximizing the production yield of the therapeutic 47Sc in the highest cross section energy range of 24–70 MeV results in the co-production of long-lived, high-γ-ray-energy 46Sc and 48Sc contaminants if one does not use enriched target materials. [...]
2024 - 28 p.
- Published in : Pharmaceuticals 17 (2024) 390
Fulltext: PDF;
|
|
|
6.
|
Scandium thermal release from activated natTi and natV target materials in mixed particle fields: Investigation of parameters relevant for isotope mass separation
/ Mamis, E (CERN ; Latvia U.) ; Kalnina, P (CERN ; Latvia U.) ; Duchemin, C (CERN) ; Lambert, L (CERN) ; Conan, N (CERN) ; Deschamps, M (CERN) ; Dorsival, A (CERN) ; Froeschl, R (CERN) ; Ruiz, F Ogallar (CERN) ; Theis, C (CERN) et al.
Scandium (Sc) has gained significant interest in nuclear medicine due to its 43Sc, 44g/mSc, and 47Sc radioactive isotopes being suitable for cancer diagnostics and therapy, offering a promising avenue for theranostics. Various production methods, including irradiation of enriched or naturally abundant calcium (Ca), titanium (Ti), and vanadium (V) materials with different particle beams, have been investigated to produce 43Sc, 44g/mSc, and 47Sc. [...]
2024 - 10 p.
- Published in : Nucl. Instrum. Methods Phys. Res., B 553 (2024) 165400
Fulltext: PDF;
|
|
|
7.
|
CERN-MEDICIS: Operational indicators to support the production of new medical radionuclides by mass-separation
/ Stora, T (CERN) ; Duchemin, C (CERN) ; Andreazza, W (CERN) ; Aubert, E (CERN) ; Bernerd, C (CERN ; Leuven U.) ; Cocolios, T (Leuven U.) ; Deschamps, M (CERN) ; Dorsival, A (CERN) ; Duraffourg, M (CERN) ; Fedosseev, V (CERN) et al.
CERN-MEDICIS is an isotope mass separation facility for biomedical R&D; located in a class A laboratory, receiving up to 50% of the 1.4GeV PSB protons. It was commissioned with radioactive ion beams in 2017. [...]
2023 - 6 p.
- Published in : J. Phys. : Conf. Ser.: 2687 (2024) , no. 8, pp. 082039
- Published in : JACoW IPAC: 2023 (2023) , pp. WEPM125
Fulltext: PublicationJACoW - PDF; PublicationIOP - PDF;
In : 14th International Particle Accelerator Conference (IPAC 2023), Venice, Italy, 7 - 12 May 2023, pp.082039
|
|
|
8.
|
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
/ Radzina, Maija (Latvia U. ; CERN) ; Saule, Laura (Latvia U.) ; Mamis, Edgars (Latvia U. ; CERN) ; Koester, Ulli (Laue-Langevin Inst.) ; Cocolios, Thomas Elias (Leuven U.) ; Pajuste, Elina (Latvia U.) ; Kalnina, Marika (Unlisted) ; Palskis, Kristaps (CERN ; Riga Tech. U.) ; Sawitzki, Zoe (Leuven U.) ; Talip, Zeynep (PSI, Villigen) et al.
Background
In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe.
Main body
A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. [...]
2023 - 16 p.
- Published in : EJNMMI Radiopharm. Chem. 8 (2023) 27
Fulltext: PDF;
|
|
|
9.
|
|
|
10.
|
The SPES laser ion source: Time structure, laser enhancement and efficiency measurements with gallium at ISOLDE Offline 2
/ Khwairakpam, O S (Siena U. ; Marseille, CPT ; INFN, Legnaro) ; Mancheva, R (CERN ; KU Leuven, Dept. Phys. Astron.) ; Au, M (CERN) ; Bernerd, C (CERN ; KU Leuven, Dept. Phys. Astron.) ; Centofante, L (INFN, Legnaro) ; Chrysalidis, K (CERN) ; Crepieux, B (CERN) ; Fedosseev, V N (CERN) ; Heinke, R (CERN) ; Marchi, T (INFN, Legnaro) et al.
The SPES laser ion source has been tested at ISOLDE Offline 2, CERN. A two-step single resonance photo-ionization scheme has been used to ionize gallium atoms in the SPES tantalum hot-cavity ion source. [...]
2024 - 10 p.
- Published in : Nucl. Instrum. Methods Phys. Res., B 548 (2024) 165249
Fulltext: PDF;
|
|